TABLE OF CONTENTS
1 INTRODUCTION 70
1.1 OBJECTIVES OF THE STUDY 70
1.2 MARKET DEFINITION 70
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET 70
1.4 LIMITATIONS 72
1.5 MARKETS COVERED 72
2 MARKET SEGMENTATION 75
2.1 MARKETS COVERED 75
2.2 GEOGRAPHICAL SCOPE 76
2.3 YEARS CONSIDERED FOR THE STUDY 77
2.4 CURRENCY AND PRICING 77
2.5 DBMR TRIPOD DATA VALIDATION MODEL 78
2.6 MULTIVARIATE MODELLING 81
2.7 PRODUCT TYPE LIFELINE CURVE 81
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 82
2.9 DBMR MARKET POSITION GRID 83
2.10 MARKET TESTING TYPE COVERAGE GRID 85
2.11 VENDOR SHARE ANALYSIS 86
2.12 SECONDARY SOURCES 87
2.13 ASSUMPTIONS 87
3 EXECUTIVE SUMMARY 88
4 PREMIUM INSIGHTS 91
4.1 PESTEL ANALYSIS 92
4.2 PORTERS FIVE FORCES 93
4.3 PIPELINE ANALYSIS 94
4.4 PATENT ANALYSIS 95
4.5 DRUG TREATMENT RATE BY MATURED MARKETS 101
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 102
4.7 PATIENT FLOW DIAGRAM 103
4.8 KEY PRICING STRATEGIES 103
4.9 KEY PATIENT ENROLLMENT STRATEGIES 104
5 LIST OF CYCLOTRONS 106
6 REGULATORY SCENARIO 107
6.1 MIDDLE EAST AND AFRICA 107
7 MARKET OVERVIEW 108
7.1 DRIVERS 110
7.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE 110
7.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS 110
7.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES 111
7.2 RESTRAINTS 111
7.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS 111
7.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS 111
7.3 OPPORTUNITIES 112
7.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS 112
7.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION 112
7.4 CHALLENGES 113
7.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS 113
7.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE 114
8 MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET, BY TYPE 115
8.1 OVERVIEW 116
8.2 DIAGNOSTIC RADIOPHARMACEUTICALS 119
8.2.1 PET RADIOPHARMACEUTICALS 120
8.2.1.1 F-18 120
8.2.1.2 RU-82 120
8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS 120
8.2.2 SPECT RADIOPHARMACEUTICALS 121
8.2.2.1 TECHNETIUM-99M 121
8.2.2.2 GALLIUM-67 121
8.2.2.3 IODINE-123 121
8.2.2.4 THALLIUM-201 121
8.2.2.5 OTHER SPECT ISOTOPES 121
8.3 THERAPEUTIC RADIOPHARMACEUTICALS 122
8.3.1 BRACHYTHERAPY ISOTOPES 123
8.3.1.1 IODINE-125 123
8.3.1.2 PALLADIUM-103 123
8.3.1.3 CESIUM-131 123
8.3.1.4 IRIDIUM-192 124
8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES 124
8.3.2 BETA EMITTERS 124
8.3.2.1 IODINE-131 124
8.3.2.2 LUTHETIUM-177 124
8.3.2.3 SAMARIUM-153 124
8.3.2.4 YTTRIUM-90 124
8.3.2.5 RHENIUM-186 125
8.3.2.6 OTHER BETA EMITTERS 125
8.3.3 ALPHA EMITTERS 125
8.3.3.1 RA-223 125
8.3.3.2 OTHERS 125
9 MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET, BY APPLICATION 126
9.1 OVERVIEW 127
9.2 DIAGNOSTIC 130
9.2.1 PET 131
9.2.1.1 ONCOLOGY 131
9.2.1.2 CARDIOLOGY 131
9.2.1.3 NEUROLOGY 131
9.2.1.4 OTHER PET APPLICATION 131
9.2.2 SPECT 132
9.2.2.1 CARDIOLOGY 132
9.2.2.2 BONE SCANS 132
9.2.2.3 THYROID APPLICATIONS 132
9.2.2.4 PULMONARY SCANS 132
9.2.2.5 OTHER SPECT APPLICATION 132
9.3 THERAPEUTIC 133
9.3.1 THYROID INDICATIONS 134
9.3.2 BONE METASTASIS 134
9.3.3 LYMPHOMA 134
9.3.4 ENDOCRINE TUMORS 134
9.3.5 OTHER INDICATIONS 134
10 MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET, BY SOURCE 135
10.1 OVERVIEW 136
10.2 NUCLEAR REACTORS 139
10.3 CYCLOTRONS 140
11 MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET, BY END USER 141
11.1 OVERVIEW 142
11.2 HOSPITALS 145
11.3 DIAGNOSTIC CENTERS 145
11.4 CANCER RESEARCH INSTITUTES 146
11.5 AMBULATORY SURGICAL CENTERS 147
11.6 OTHERS 148
12 MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET, BY REGION 149
12.1 MIDDLE EAST AND AFRICA 150
12.1.1 SOUTH AFRICA 161
12.1.2 EGYPT 168
12.1.3 SAUDI ARABIA 174
12.1.4 U.A.E. 181
12.1.5 KUWAIT 188
12.1.6 ISRAEL 195
12.1.7 REST OF MIDDLE EAST AND AFRICA 202
13 MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE 203
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 203
14 SWOT ANALYSIS 204
15 COMPANY PROFILE 205
15.1 CARDINAL HEALTH 205
15.1.1 COMPANY SNAPSHOT 205
15.1.2 REVENUE ANALYSIS 205
15.1.3 COMPANY SHARE ANALYSIS 206
15.1.4 PRODUCT PORTFOLIO 206
15.1.5 RECENT DEVELOPMENT 207
15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY 208
15.2.1 COMPANY SNAPSHOT 208
15.2.2 REVENUE ANALYSIS 208
15.2.3 COMPANY SHARE ANALYSIS 209
15.2.4 PRODUCT PORTFOLIO 209
15.2.5 RECENT DEVELOPMENT 209
15.3 LANTHEUS 210
15.3.1 COMPANY SNAPSHOT 210
15.3.2 REVENUE ANALYSIS 210
15.3.3 COMPANY SHARE ANALYSIS 211
15.3.4 PRODUCT PORTFOLIO 211
15.3.5 RECENT DEVELOPMENT 211
15.4 CURIUM 212
15.4.1 COMPANY SNAPSHOT 212
15.4.2 COMPANY SHARE ANALYSIS 212
15.4.3 PRODUCT PORTFOLIO 213
15.4.4 RECENT DEVELOPMENT 213
15.5 GENERAL ELECTRIC COMPANY 214
15.5.1 COMPANY SNAPSHOT 214
15.5.2 REVENUE ANALYSIS 214
15.5.3 COMPANY SHARE ANALYSIS 215
15.5.4 PRODUCT PORTFOLIO 215
15.5.5 RECENT DEVELOPMENT 215
15.6 BRACCO 216
15.6.1 COMPANY SNAPSHOT 216
15.6.2 PRODUCT PORTFOLIO 216
15.6.3 RECENT DEVELOPMENT 216
15.7 BWX TECHNOLOGIES. INC. 217
15.7.1 COMPANY SNAPSHOT 217
15.7.2 REVENUE ANALYSIS 217
15.7.3 PRODUCT PORTFOLIO 218
15.7.4 RECENT DEVELOPMENT 218
15.8 CHINA ISOTOPE & RADIATION CORPORATION 219
15.8.1 COMPANY SNAPSHOT 219
15.8.2 REVENUE ANALYSIS 219
15.8.3 PRODUCT PORTFOLIO 220
15.8.4 RECENT DEVELOPMENT 220
15.9 COQUI RADIOPHARMACEUTICALS CORP. 221
15.9.1 COMPANY SNAPSHOT 221
15.9.2 PRODUCT PORTFOLIO 221
15.9.3 RECENT DEVELOPMENT 221
15.10 ECKERT & ZIEGLER 222
15.10.1 COMPANY SNAPSHOT 222
15.10.2 REVENUE ANALYSIS 222
15.10.3 PRODUCT PORTFOLIO 223
15.10.4 RECENT DEVELOPMENT 223
15.11 ECZACIBAI-MONROL 224
15.11.1 COMPANY SNAPSHOT 224
15.11.2 PRODUCT PORTFOLIO 224
15.11.3 RECENT DEVELOPMENT 224
15.12 EVERGREEN THERAGNOSTICS, INC. 225
15.12.1 COMPANY SNAPSHOT 225
15.12.2 PRODUCT PORTFOLIO 225
15.12.3 RECENT DEVELOPMENT 225
15.13 MIDDLE EAST & AFRICA MEDICAL SOLUTIONS 226
15.13.1 COMPANY SNAPSHOT 226
15.13.2 PRODUCT PORTFOLIO 226
15.13.3 RECENT DEVELOPMENT 226
15.14 IBA WORLDWIDE 227
15.14.1 COMPANY SNAPSHOT 227
15.14.2 REVENUE ANALYSIS 227
15.14.3 PRODUCT PORTFOLIO 228
15.14.4 RECENT DEVELOPMENT 228
15.15 INSTITUTE OF ISOTOPES 229
15.15.1 COMPANY SNAPSHOT 229
15.15.2 PRODUCT PORTFOLIO 229
15.15.3 RECENT DEVELOPMENT 229
15.16 ISOTOPE JSC 230
15.16.1 COMPANY SNAPSHOT 230
15.16.2 PRODUCT PORTFOLIO 230
15.16.3 RECENT DEVELOPMENT 230
15.17 JUBILANT RADIOPHARMA A JUBILANT PHARMOVA COMPANY 231
15.17.1 COMPANY SNAPSHOT 231
15.17.2 REVENUE ANALYSIS 231
15.17.3 PRODUCT PORTFOLIO 232
15.17.4 RECENT DEVELOPMENT 232
15.18 NTP 233
15.18.1 COMPANY SNAPSHOT 233
15.18.2 PRODUCT PORTFOLIO 233
15.18.3 RECENT DEVELOPMENT 233
15.19 PHARMALOGIC HOLDINGS CORP 234
15.19.1 COMPANY SNAPSHOT 234
15.19.2 PRODUCT PORTFOLIO 234
15.19.3 RECENT DEVELOPMENT 234
15.20 SHINE TECHNOLOGIES, LLC 235
15.20.1 COMPANY SNAPSHOT 235
15.20.2 PRODUCT PORTFOLIO 235
15.20.3 RECENT DEVELOPMENT 235
15.21 SIEMENS HEALTHCARE GMBH 236
15.21.1 COMPANY SNAPSHOT 236
15.21.2 REVENUE ANALYSIS 236
15.21.3 PRODUCT PORTFOLIO 237
15.21.4 RECENT DEVELOPMENT 237
16 QUESTIONNAIRE 238
17 RELATED REPORTS 241

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.